Among the most clinically relevant discoveries enabled by these technologies are novel fusion genes, such as MEF2D and ZNF384 rearrangements, which define distinct subtypes of B-ALL with characteristic transcriptional profiles, immunophenotypic features, and prognostic implications [35,36,37,38,39]. This evidence concerns the gene MEF2D and precursor B-cell acute lymphoblastic leukemia.